Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists
A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with type 2 diabetes mellitus (T2DM) initiated with dapagliflozin by general practitioners (GPs) and endocrinologists in real-life setting. It is anticipated that patient recruitment will last 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit. There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose
Visão geral do estudo
Status
Condições
Descrição detalhada
Study design:
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with T2DM initiated with dapagliflozin by GPs and endocrinologists in real-life setting.
Only patients, who provide written consent to participate in the study will be enrolled into this study. All patients will be unique with no overlap between endocrinologists and GPs. All consecutive patients managed by GPs or endocrinologists who meet inclusion criteria will be included. All GPs and endocrinologists, who manage T2DM on sites, will be participating investigators.
Patients will undergo clinical assessment and receive the standard medical care as usual determined by the treating doctor based on their clinical judgement and national guidelines. Patients will not receive experimental treatment as a consequence of their participation in the observational study.
It is anticipated that patient recruitment will last for 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit.
There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose.
Data Source(s):
Baseline data will be collected during Visit 1 from the T2DM patient medical records, including disease history of patient, and during follow-up data during Visit 2 (after 6±3 months from Visit 1).
Study Population:
It is planned to include 900 male and female T2DM outpatients 18 years and older, who were managed by GPs or endocrinologists in 45 outpatient sites.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Belgorod Region, Shebekino, Federação Russa, D1690R00037
- Research Site
-
Belgorod Region, Volokonovsky R-n, P. Volokonovka, Federação Russa, D1690R00037
- Research Site
-
Gis-Khrustalny, Federação Russa, D1690R00037
- Research Site
-
Izhevsk, Federação Russa, D1690R00037
- Research Site
-
Kazan, Federação Russa, D1690R00037
- Research Site
-
Lipetsk, Federação Russa, D1690R00037
- Research Site
-
N. Novgorod, Federação Russa, D1690R00037
- Research Site
-
N. Novgorod Region, Federação Russa, D1690R00037
- Research Site
-
Novomoskovsk, Federação Russa, D1690R00037
- Research Site
-
Novosibirsk, Federação Russa, D1690R00037
- Research Site
-
Perm, Federação Russa, D1690R00037
- Research Site
-
Ryazan, Federação Russa, D1690R00037
- Research Site
-
Samara, Federação Russa, D1690R00037
- Research Site
-
St-petersburg, Federação Russa, D1690R00037
- Research Site
-
Tambov Region, Federação Russa, D1690R00037
- Research Site
-
Volzhsk, Federação Russa, D1690R00037
- Research Site
-
Voronezh, Federação Russa, D1690R00037
- Research Site
-
Voronezh Region, Novovoronezh, Federação Russa, D1690R00037
- Research Site
-
Yaroslavl, Federação Russa, D1690R00037
- Research Site
-
Yoshkar-Ola, Federação Russa, D1690R00037
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 18 and older;
- Established diagnosis of T2DM (ICD-10 code E11.2-E11.9)
- The current treatment with dapagliflozin prescribed at least 1 month before the FSI;
- Written voluntary informed consent has been provided
- Management in outpatient setting.
Exclusion Criteria:
- Type 1 diabetes
- Current participation in a clinical trial
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
- Presence of serious/severe co-morbidities in the opinion of the investigator, which may limit treatment approach as usual.
- Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the 1st Visit
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Demographic parameters before dapagliflozin initiation in T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
mean age
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
age distribution
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
gender distribution
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
mean duration of T2DM
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
HbA1c (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Weight (mean)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
SBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
DBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Proportion of T2DM patients with diabetic complications
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Proportion of patients with T2DM treatment intensification during 3 months before inclusion in the study
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Proportion of patients with different treatment regimen
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Proportion of patients on treatment with different classes of antidiabetic therapy
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Prazo: 3 months before dapagliflozin initiation
|
Proportion of patients on different classes of concomitant therapy
|
3 months before dapagliflozin initiation
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Vladimir Bulatov, MD, PhD, AstraZeneca Russia
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- D1690R00037
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .